Skip to main content
. Author manuscript; available in PMC: 2021 Feb 17.
Published in final edited form as: Br J Haematol. 2019 Jul 15;187(4):488–501. doi: 10.1111/bjh.16092

Figure 1. Anti-proliferative effects of BLU-285 and FLT3 inhibitors on growth of oncogene-driven Ba/F3 cell lines.

Figure 1.

(A) Anti-proliferative effects of BLU-285 and FLT3 inhibitors (100 nM) on growth of Ba/F3 cells driven by oncogenic FLT3 (Ba/F3-FLT3-ITD) or hyperactivated FLT3 (Ba/F3.FLT3.CBL.Ins (SK366) and Ba/F3.FLT3.CBL.Y371H) versus Ba/F3 cells driven by other oncogenes (Ba/F3.p210, Ba/F3-EPOR+JAK2-V617F, Ba/F3-KRAS-G12D), following 3 days of treatment. (B-C) Comparison of effects of BLU-285 and FLT3 inhibitors against Ba/F3-FLT3-ITD versus Ba/F3-FLT3-ITD+F691L cells and Ba/F3-D835Y cells at 1 nM (B) and 10 nM (C).